Imugene Ltd has released a press release.
Imugene Receives $4.82 million R&D Tax Incentive
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Imugene First Patient Dosed in PD1-VAXX Clinical Trial
- Imugene HER Vaxx shows positive Overall Survival in trial
- Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
- Imugene Immunotherapy Combination Patent Granted in US
- Imugene Secures $5.7 million Option Underwriting Agreement
Later from Imugene
- Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
- Imugene completes recruitment to her-vaxx phase 2 trialim
- Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
- Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
- Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene